Sign in

Private company

Aptose Biosciences Inc.

Aptose Biosciences Inc. is a Canadian biological products company based in Toronto, incorporated in Ontario.2

Last updated Oct 21, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersToronto, Canada2
  • Incorporated inOntario, Canada3
  • Business address66 Wellington Street West, Suite 5300, Td Bank Tower Box 48, Toronto3
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formBusiness corporations (which includes professional corporations)2
  • LEI5299003EUHV3CD08L9492
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered address251 Consumers Road, Suite 1105, M2J 4R3 Toronto, Canada2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-$22.0MFree cash flow5

Financial statements

Revenue67895$0 in 2025
02020: $0$020202021: $0$020212022: $0$020222023: $0$020232024: $0$020242025: $0$02025
Net income1067895-$25.5M in 2025−3% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$26.3M-$26.3M20192020: -$55.2M-$55.2M2020+110%2021: -$65.4M-$65.4M2021+18%2022: -$41.8M-$41.8M2022−36%2023: -$51.2M-$51.2M2023+22%2024: -$25.4M-$25.4M2024−50%2025: -$25.5M-$25.5M2025+0%
Fiscal year2019202020212022202320242025
Revenue$06$07$08$09$05$05
Research and development$16.8M10$29.3M6$46.0M7$24.5M8$33.3M9$15.1M5$11.3M5
Operating expenses$65.4M7$42.6M8$52.4M9$26.3M5$24.7M5
Income tax$05$05
Net income-$26.3M10-$55.2M6-$65.4M7-$41.8M8-$51.2M9-$25.4M5-$25.5M5
Earnings per share-$0.737-$6.808-$227.439-$36.385-$10.415
Earnings per share (diluted)-$0.737-$6.808-$227.439-$36.385-$10.415
Shares (weighted, basic)89.1K shares76.2M shares8225.2K shares9699.0K shares52.4M shares5
Shares (weighted, diluted)89.1K shares76.2M shares8225.2K shares9699.0K shares52.4M shares5

Compare Aptose Biosciences Inc. with another company

Corporate structure

Aptose Biosciences Inc. sits at the top of its group. 3 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Aptose Biosciences Inc.

  • Bleichroeder LP Filed SCHEDULE 13G/A on Aptose Biosciences Inc., latest Aug 14, 2025 (5 filings since Feb 13, 2025)
  • Hanmi Pharmaceutical Filed SCHEDULE 13D/A on Aptose Biosciences Inc., latest Mar 20, 2025 (4 filings since Sep 12, 2023)
  • ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on Aptose Biosciences Inc., latest Feb 14, 2025 (2 filings since Nov 14, 2024)
  • Nantahala Capital Management, LLC Filed SC 13G/A on Aptose Biosciences Inc., latest Feb 14, 2024 (3 filings since Feb 14, 2022)
  • Aaron G.l. Fletcher Filed SC 13G on Aptose Biosciences Inc., latest Jan 17, 2023
  • ORBIMED CAPITAL LLC Filed SC 13G/A on Aptose Biosciences Inc., latest Feb 11, 2022
  • Aptose Biosciences Inc. Toronto, Ontario, Canada
    • Aptose Biosciences U.S. Inc. Subsidiary · Delaware, United States
    • NuChem Pharmaceuticals Inc. Subsidiary · Ontario, Canada

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Aptose Biosciences Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$512.0K5 Dec 31, 2025$544.0K5 Dec 31, 2024−5.9%
Accumulated depreciation$508.0K5 Dec 31, 2025$518.0K5 Dec 31, 2024−1.9%
Property and equipment, net$4.0K5 Dec 31, 2025$26.0K5 Dec 31, 2024−84.6%
Operating-lease assets (leased space)$175.0K5 Dec 31, 2025$571.0K5 Dec 31, 2024−69.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$935.0K5 Dec 31, 2025$6.2M5 Dec 31, 2024−84.8%

Properties, in its own words

Our headquarters are located at 66 Wellington Street West Suite 5300, TD Bank Tower Box 48 Toronto ON M5K 1E6, and our executive offices are located at 12770 High Bluff Drive, Suite 120, San Diego, CA 92130 (telephone: 858-926-2730). The lease for 7,556 square feet of office space in San Diego is scheduled to expire on May 31, 2026.

Item 2 of the 10-K filed Mar 31, 2026.14

Leadership

Who has led Aptose Biosciences Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. William G. Rice2018–now

Chair

  1. William G. Rice2018–now

President

  1. William G. Rice2018–now

Chief financial officer

  1. Gregory K. Chow2018–2021
  2. Jotin Marango2021–2022
  3. Fletcher Payne2024
20202025
Board members and other officers (10)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Aptose Biosciences U.S. Inc. Delaware4
  • NuChem Pharmaceuticals Inc. Ontario, Canada4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.)Sep 8, 2014 to Nov 26, 20143
  • LORUS THERAPEUTICS INCJul 10, 2002 to Sep 2, 20143
  • IMUTEC PHARMA INCFeb 14, 1997 to Mar 24, 19983

Timeline

  1. Jul 1, 20268-K Regulation FD disclosure29
  2. Jul 1, 20268-K Completed an acquisition or sale; Change to shareholders' rights; Change in control30
  3. Jun 15, 20268-K Regulation FD disclosure31
  4. May 29, 20268-K Regulation FD disclosure32
  5. May 13, 20268-K Results of operations33
  6. Apr 30, 20268-K Regulation FD disclosure34
  7. Mar 31, 20268-K Shareholder vote35
  8. Mar 31, 20268-K Regulation FD disclosure36
  9. Mar 23, 20268-K Regulation FD disclosure37
  10. Mar 23, 20268-K Entered a material agreement; Executive or director change38
  11. Mar 19, 20268-K Regulation FD disclosure39
  12. Feb 24, 20268-K Entered a material agreement; New debt or obligation; Regulation FD disclosure40
  13. Dec 21, 2018New chief executive William G. Rice becomes CEO15

Calendar

When it reported results

  1. May 13, 2026Reported quarterly or annual results33
  2. Nov 13, 2025Reported quarterly or annual results41
  3. Aug 13, 2025Reported quarterly or annual results42
  4. May 8, 2025Reported quarterly or annual results43
  5. Mar 28, 2025Reported quarterly or annual results44
  6. Nov 8, 2024Reported quarterly or annual results45
  7. Aug 8, 2024Reported quarterly or annual results46
  8. May 14, 2024Reported quarterly or annual results47

Drug trials and FDA: coming up

  1. Nov 2026Phase 1/2 trial readout expected Phase 1/2 trial of Tuspetinib, Venetoclax Oral Tablet and others in Leukemia, Myeloid, Acute: primary completion expected Nov 2026 (ClinicalTrials.gov NCT03850574).48

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

317 filings to the SEC since October 2021: 6 annual reports, 14 quarterly reports, 146 major events, 62 insider forms, 16 large holders, 73 other. The latest 20:

  1. Jul 2, 20264 EDGAR
  2. Jul 1, 202615-12G EDGAR
  3. Jul 1, 2026SC 13E3/A EDGAR
  4. Jul 1, 20268-K EDGAR
  5. Jul 1, 20268-K EDGAR
  6. Jul 1, 20264 EDGAR
  7. Jul 1, 20264 EDGAR
  8. Jul 1, 20264 EDGAR
  9. Jul 1, 20264 EDGAR
  10. Jul 1, 20264 EDGAR
  11. Jul 1, 20264 EDGAR
  12. Jul 1, 20264 EDGAR
  13. Jun 15, 20268-K EDGAR
  14. May 29, 20268-K EDGAR
  15. May 13, 202610-Q EDGAR
  16. May 13, 20268-K EDGAR
  17. Apr 30, 20268-K EDGAR
  18. Apr 1, 2026SC 13E3/A EDGAR
  19. Apr 1, 2026UPLOAD EDGAR
  20. Mar 31, 202610-K EDGAR

The 317 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

12 open-market trades by officers, directors and large owners since October 2021: 12 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 25, 2024Rice William G.Chair, President & CEOBuy100,000$0.20$20.0KForm 4
Sep 22, 2023Seizinger Bernd R.Buy17,000$3.14$53.4KForm 4
Sep 19, 2022Rice William G.Chair, President & CEOBuy10,000$0.68$6.8KForm 4
Sep 19, 2022Payne FletcherBuy10,000$0.68$6.8KForm 4
Jun 6, 2022Rice William G.Chair, President & CEOBuy10,000$0.97$9.7KForm 4
Dec 20, 2021BURGER DENIS RBuy10,000$1.45$14.5KForm 4
Dec 16, 2021PLATZER ERICHBuy100,000$1.38$137.9KForm 4
Dec 16, 2021Rice William G.Chair, President & CEOBuy13,183$1.52$20.0KForm 4
Dec 15, 2021PLATZER ERICHBuy270,000$1.17$316.9KForm 4
Dec 15, 2021Rice William G.Chair, President & CEOBuy17,822$1.12$20.0KForm 4
Nov 26, 2021Rice William G.Chair, President & CEOBuy8,643$2.31$20.0KForm 4
Nov 19, 2021Bejar RafaelBuy10,000$2.56$25.6KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024ChairmanPresident and$1.1M55
2024Senior VicePresident and Chief$762.2K55
2024Senior Vice PresidentChief Financial$747.8K55
2023Chief Executive Officer$924.7K55
2023Medical Officer$750.1K55
2023Officer and Chief Business Officer$611.4K55

SEC filer profile

How Aptose Biosciences Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAptose Biosciences Inc.1
  • CIK0000882361
  • Employer ID (EIN)98-113680214
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company14
  • Incorporated inCanada14
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address66 Wellington Street West, Suite 5300, Td Bank Tower Box 48, Toronto, Ontario, Canada1
  • Phone310-849-80601
  • Shares outstanding2,552,429 as of May 13, 202613
  • Public float$22.1M as of Jun 28, 202414
  • AuditorErnst & Young LLP, Toronto, Canada PCAOB ID 1263; no auditor attestation of internal control over financial reporting14
  • On EDGAR sinceFeb 14, 19971
  • Filings1,080 in all: 6-K (438), 8-K (207), 4 (113), SC 13G/A (31), 10-Q (22), SC 13D/A (22), CORRESP (21), SC 13G (18)1
    All 62 form types

    UPLOAD (18), 424B5 (16), 3 (15), 20-F (13), 4/A (11), EFFECT (10), 6-K/A (9), DEF 14A (9), 10-K (8), PRE 14A (6), S-1/A (5), SC 13E3/A (5), SCHEDULE 13G/A (5), 10-K/A (4), 40-F (4), F-X (4), PRER14A (4), S-1 (4), S-8 (4), 424B2 (3), 424B3 (3), S-3 (3), SC 13D (3), 20-F/A (2), 25-NSE (2), 424B4 (2), 8-A12B (2), CB (2), CT ORDER (2), DEFA14A (2), F-1 (2), F-1/A (2), RW (2), SUPPL (2), 15-12G (1), 25 (1), 8-K/A (1), CERTAMX (1), CERTNAS (1), D (1), DEFM14A (1), F-10 (1), F-10/A (1), F-3 (1), F-3/A (1), NT 20-F (1), POS AM (1), PREM14A (1), S-1MEF (1), S-3/A (1), S-8 POS (1), SC 13E3 (1), SCHEDULE 13D/A (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) May 13, 2026
    Proxy statement (DEF 14A) Apr 28, 2025
    Latest 8-K (8-K) Jul 1, 2026

Risk factors and legal proceedings

The risks Aptose Biosciences Inc. names in Item 1A of its 10-K filed Mar 31, 2026: 54 risks under these headings, as written.14

  • Risks Related to the Plan of Arrangement
  • There is no assurance when or if the Arrangement will be completed.
  • Failure to complete the Arrangement could negatively impact the market price of the Company's Common Shares and the Company's future business and financial results.
  • The application of interim operating covenants may restrict the Company's ability to pursue certain opportunities.
  • Aptose and Hanmi may be the targets of legal claims, securities class actions, derivative lawsuits and other claims and negative publicity related to the Arrangement.
  • No Equity Interest in the Company Following the Arrangement
  • The Diversion of the Attention of Management
  • Uncertainty Surrounding the Arrangement
  • The Company will incur costs and may have to pay an Expense Fee.
  • CCAA Plan in the Event Arrangement is not Completed
  • Certain directors and executive officers of the Company may have interests in the Arrangement that may be different from, or in addition to, the interests of Shareholders generally.
  • Risks Related to our Business
The other 46 risks
  • There is substantial doubt that we can remain a going concern over the next twelve months.
  • We are an early-stage development company with no revenues from product sales.
  • We need to raise additional capital.
  • Our operations could be adversely affected by events outside of our control, such as natural disasters, wars or health crises.
  • We have a history of operating losses. We expect to incur net losses and we may never achieve or maintain profitability.
  • We heavily rely on the capabilities and experience of our key executives and scientists and the loss of any of them could affect our ability to develop our products.
  • Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.
  • We may expand our business through the acquisition of companies or businesses or by entering into collaborations or by in-licensing product candidates, each of which could disrupt our business and harm our financial condition.
  • Risks Related to Development, Clinical Testing and Regulatory Approval of Our Product Candidates
  • Fast Track Designation by the FDA may not lead to a faster development or regulatory review or approval process.
  • Clinical trials are long, expensive and uncertain processes and the FDA or Health Canada may ultimately not approve any of our product candidates. We may never develop any commercial drugs or other products that generate revenues.
  • We may choose to expend our limited resources on programs that do not yield successful product candidates as opposed to indications that may be more profitable or for which there is a greater likelihood of success.
  • We may not achieve our projected development goals in the time frames we announce and expect.
  • Government funding cuts may impact our federal research initiatives.
  • Delays in clinical testing could result in delays in commercializing our product candidates and our business may be substantially harmed.
  • We rely on contract manufacturers over whom we have limited control. If we are subject to quality, cost or delivery issues with the preclinical and clinical grade materials supplied by contract manufacturers, our business operations could suffer significant harm.
  • Some components of our products are manufactured by third parties outside of the United States, and our business may be harmed by legal, regulatory, economic, political and public health risks associated with international trade and those markets.
  • If we have difficulty enrolling patients in clinical trials, the completion of the trials may be delayed or canceled.
  • If we are unable to successfully develop companion diagnostics for our therapeutic product candidates, or experience significant delays in doing so, we may not achieve marketing approval or realize the full commercial potential of our therapeutic product candidates.
  • We rely and will continue to rely on third parties to conduct and monitor many of our preclinical studies and our clinical trials, and their failure to perform as required could cause substantial harm to our business.
  • Negative results from clinical trials or studies of others and adverse safety events involving the targets of our products may have an adverse impact on our future commercialization efforts.
  • The design or our execution of clinical trials may not support regulatory approval.
  • As a result of intense competition and technological change in the biotechnical and pharmaceutical industries, the marketplace may not accept our products or product candidates, and we may not be able to compete successfully against other companies in our industry and achieve profitability.
  • Risks Related to our Intellectual Property
  • We may be unable to obtain patents to protect our technologies from other companies with competitive products, and patents of other companies could prevent us from manufacturing, developing or marketing our products.
  • Patent protection
  • Enforcement of intellectual property rights
  • Our products and product candidates may infringe the intellectual property rights of others, or others may infringe on our intellectual property rights which could increase our costs.
  • We may incur substantial cost in defending our intellectual property.
  • We have licensed important portions of our intellectual property from Hanmi, and are subject to significant obligations under those license agreements.
  • Our business depends, in part, on our ability to use technology that we have licensed or will in the future license from third parties, and, if these licenses were terminated or if we were unable to license additional technology we may need in the future, our business will be adversely affected.
  • Legal and Regulatory Risk
  • Our ability to develop, produce and market our products is subject to extensive government regulation.
  • Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may adversely affect the prices we may obtain.
  • We are subject to U.S. and Canadian healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, fines, disgorgement, exclusion from participation in government healthcare programs, curtailment or restricting of our operations and diminished profits and future earnings.
  • If product liability, clinical trial liability or environmental liability claims are brought against us or we are unable to obtain or maintain product liability, clinical trial or environmental liability insurance, we may incur substantial liabilities that could reduce our financial resources.
  • If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
  • Risks Related to Our Common Shares
  • Our share price has been and is likely to continue to be volatile and an investment in our Common Shares could suffer a decline in value.
  • Future sales of our Common Shares by us or by our existing shareholders could cause our share price to fall.
  • We are susceptible to stress in the global economy and therefore, our business may be affected by the current and future global financial conditions.
  • Failure to meet the TSX's continued listing requirements could result in the delisting of our Common Shares, negatively impact the price of our Common Shares and negatively impact our ability to raise additional capital.
  • Compliance with changing corporate governance regulations and public disclosure may result in additional expenses.
  • Certain Canadian laws could delay or deter a change of control.
  • The exercise of all or any number of outstanding stock options, the award of any additional options, warrants, restricted stock units or other stock-based awards or any issuance of shares to raise funds or acquire a business may dilute your Common Shares.
  • We do not expect to pay dividends for the foreseeable future.
  • General Risks
  • It may be difficult for non-Canadian investors to obtain and enforce judgments against us because of our Canadian incorporation and presence.
  • We are likely a “passive foreign investment company” which may have adverse United States federal income tax consequences for United States shareholders.
  • Any failure to maintain an effective system of internal control may result in material misstatements of our consolidated financial statements or cause us to fail to meet our reporting obligations or fail to prevent fraud; and in that case, our shareholders could lose confidence in our financial reporting, which would harm our business and could negatively impact the price of our Common Shares.
  • Data security incidents and privacy breaches could result in important remediation costs, increased cyber security costs, litigation and reputational harm.
  • We must successfully upgrade and maintain our information technology systems.

Legal proceedings

We know of no material pending legal proceedings to which our company or subsidiaries is a party or of which any of our properties, or the properties of our subsidiaries, is the subject. However, from time to time, we may be subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of our business. Such matters are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time.

The opening of Item 3, Legal Proceedings.14

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55